NCT02326090View on ClinicalTrials.gov

Phase 2 Study With Cis-UCA Ophthalmic Solutions in Subjects With Dry Eye

PHASE2CompletedINTERVENTIONAL
Enrollment

161

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

April 30, 2015

Study Completion Date

April 30, 2015

Conditions
Dry Eye Syndrome
Interventions
DRUG

cis-UCA ophthalmic solution 1.0%

DRUG

cis-UCA ophthalmic solution 2.5%

DRUG

Placebo ophthalmic solution

Trial Locations (1)

01810

Andover

Sponsors
All Listed Sponsors
collaborator

ORA, Inc.

INDUSTRY

lead

Herantis Pharma Plc.

INDUSTRY

NCT02326090 - Phase 2 Study With Cis-UCA Ophthalmic Solutions in Subjects With Dry Eye | Biotech Hunter | Biotech Hunter